Research and Development Expenses Breakdown: Alpine Immune Sciences, Inc. vs ADMA Biologics, Inc.

Biotech R&D: Alpine vs. ADMA - A Decade of Spending

__timestampADMA Biologics, Inc.Alpine Immune Sciences, Inc.
Wednesday, January 1, 2014951701412199547
Thursday, January 1, 2015701594616054000
Friday, January 1, 2016768823823316000
Sunday, January 1, 2017622958710626000
Monday, January 1, 2018392612028970000
Tuesday, January 1, 2019234384835847000
Wednesday, January 1, 2020590701327185000
Friday, January 1, 2021364606058742000
Saturday, January 1, 2022361376470243000
Sunday, January 1, 2023330000080904000
Loading chart...

In pursuit of knowledge

A Decade of Innovation: R&D Spending in Biotech

In the competitive world of biotechnology, research and development (R&D) spending is a critical indicator of a company's commitment to innovation. Over the past decade, Alpine Immune Sciences, Inc. and ADMA Biologics, Inc. have demonstrated contrasting strategies in their R&D investments.

From 2014 to 2023, Alpine Immune Sciences, Inc. has consistently increased its R&D expenses, peaking at approximately $81 million in 2023, a remarkable 560% increase from 2014. This upward trend underscores their aggressive pursuit of cutting-edge therapies. In contrast, ADMA Biologics, Inc. has shown a more conservative approach, with R&D spending decreasing by about 65% over the same period, from $9.5 million in 2014 to $3.3 million in 2023.

These spending patterns reflect each company's strategic priorities and market positioning, offering valuable insights into their future growth trajectories.

Published by
U.S. Securities and Exchange Commission

Source link
sec.gov

Date published
17 Jan 2025